Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus

Annals of Surgery

Volumn 251, Issue 5, 2010, Pages 857-864

  Lurje, Georg ^a,b   Leers, Jessica M ^c   Pohl, Alexandra ^a   Oezcelik, Arzu ^c   Zhang, Wu ^a   Ayazi, Shahin ^c   Winder, Thomas ^a   Ning, Yan ^a   Yang, Dongyun ^a   Klipfel, Nancy E ^d   Chandrasoma, Parakrama ^d   Hagen, Jeffrey A ^c   Demeester, Steven R ^c   Demeester, Tom R ^c   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Departments of Surgery   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DNA; EPIDERMAL GROWTH FACTOR; FORMALDEHYDE; MOLECULAR MARKER; PARAFFIN; PROTEINASE ACTIVATED RECEPTOR 1;

ALLELE; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; DNA ISOLATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; GENE INSERTION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ENDOSTATINS; EPIDERMAL GROWTH FACTOR; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-8; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PAR-1; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77951693104     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181c97fcf     Document Type: Article

References (44)

1. Bollschweiler E, Wolfgarten E, Gutschow C, et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 2001;92:549-555.
2. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-146. (Pubitemid 40277094)
3. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol. 1999;26:2-8.
4. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83: 2049-2053.
5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
6. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-2252.
7. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805.
8. Holscher AH, Schneider PM, Gutschow C, et al. Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg. 2007; 245:241-246.
9. Peyre CG, Demeester SR, Rizzetto C, et al. Vagal-sparing esophagectomy: the ideal operation for intramucosal adenocarcinoma and barrett with high-grade dysplasia. Ann Surg. 2007;246:665-674.
10. Hagen JA, DeMeester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001; 234:520-530; discussion 530-531.
11. Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549-556.
12. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545-553.
13. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-1027.
14. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
15. Stoeltzing O, McCarty MF, Wey JS, et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst. 2004;96:946-956.
16. Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998;4:909-914.
17. Lurje G, Hendifar AE, Schultheis AM, et al. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics. 2009;19:95-102.
18. Ma L, Perini R, McKnight W, et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA. 2005;102:216-220.
19. Italiano JE Jr, Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008;111: 1227-1233.
20. Pinedo HM, Verheul HM, D'Amato RJ, et al. Involvement of platelets in tumour angiogenesis? Lancet. 1998;352:1775-1777.
21. Leers JM, DeMeester SR, Chan N, et al. Clinical characteristics, biological behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg. 2009;138:594-602.
22. Lurje G, Nagashima F, Zhang W, et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res. 2008;14:7884-7895.
23. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
24. Kisucka J, Butterfield CE, Duda DG, et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA. 2006;103:855-860.
25. Daly ME, Makris A, Reed M, et al. Hemostatic regulators of tumor angio-genesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst. 2003;95:1660-1673.
26. Vu TK, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
27. Vu TK, Wheaton VI, Hung DT, et al. Domains specifying thrombin-receptor interaction. Nature. 1991;353:674-677.
28. Gerszten RE, Chen J, Ishii M, et al. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature. 1994;368:648-651.
29. Ma L, Elliott SN, Cirino G, et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA. 2001;98:6470-6475.
30. Ward EG, Grosios K, Markham AF, et al. Genomic structures of the human angiopoietins show polymorphism in angiopoietin-2. Cytogenet Cell Genet. 2001;94:147-154.
31. Darmoul D, Gratio V, Devaud H, et al. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol. 2003;162:1503-1513.
32. Li F, Baykal D, Horaist C, et al. Cloning and identification of regulatory sequences of the human thrombin receptor gene. J Biol Chem. 1996;271: 26320-26328.
33. Kamura T, Handa H, Hamasaki N, et al. Characterization of the human thrombopoietin gene promoter. A possible role of an Ets transcription factor, E4TF1/GABP. J Biol Chem. 1997;272:11361-11368.
34. Arnaud E, Nicaud V, Poirier O, et al. Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thrombo-embolism. Arterioscler Thromb Vasc Biol. 2000;20:585-592.
35. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus. 2006;19:425-432.
36. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
37. Hickey K, Grehan D, Reid IM, et al. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer. 1994;74:1693-1698.
38. Schneider S, Uchida K, Brabender J, et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg. 2005;200:336-344.
39. Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005;93:107-115.
40. Inada S, Koto T, Futami K, et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today. 1999;29:493-503.
41. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002;94:1593-1611.
42. Ali-Osman F, Ii JEH, Adams B, et al. Genetic polymorphism of the Epidermal Growth Factor (EGF) gene in glioma patients: distribution and correlation with Survival. AACR Meet Abstr. 2006;285-b.
43. Graziano F, Ruzzo A, Loupakis F, et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colo-rectal cancer. J Clin Oncol. 2008;26:1427-1434.
44. Lanuti M, Liu G, Goodwin JM, et al. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res. 2008;14:3216-3222.